Precision Medicine

Precision Medicine

Targeted Oncology presents Precision Medicine, a video series featuring oncology experts discussing how to use a more customized approach when treating patients with cancer.


The Role of CD19 in the Targeted Treatment of Relapsed/Refractory DLBCL

September 15th 2021

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, discuss the importance of CD19-targeted therapy as a promising option in the relapsed/refractory DLBCL setting.

Selective Immunomodulating Microtubule Binding Agents (SIMBA): A Novel Approach To Chemotherapy-Induced Neutropenia

September 2nd 2021

Future implications for palliative therapy with selective immunomodulating microtubule binding agents as prevention against chemotherapy-induced neutropenia in high-risk patients with solid tumors.

EGFR Exon 20 Insertion as a Therapeutic Target in Non-small Cell Lung Cancer

August 12th 2021

Joel Neal, MD, PhD, and Alexander I. Spira, MD, PhD, FACP, talk about the role of EGFR, particularly exon 20 insertion, in NSCLC growth and progression, and review the mechanism of action and current safety and efficacy data from the mobocertinib trial.

CD19 As a Therapeutic Target In Diffuse Large B-Cell Lymphoma

July 30th 2021

Experts discuss the role of CD19 in the therapeutic landscape for patients with transplant-ineligible relapsed/refractory DLBCL.

Targeting JAK2 in Myeloproliferative Neoplasms

July 14th 2021

A discussion ofJAK2-directed therapies, their roles in treatment, and the key clinical trials guiding their use in myeloproliferative neoplasms. Also discussed are some relevant data recently presented at ASCO.

The Role of PI3K Inhibitors in Relapsed/Refractory FL and MZL

May 20th 2021

Jason M. Melear, MD, and Ian W. Flinn, MD, PhD, discuss the role of PI3K inhibitors in the management of R/R follicular lymphoma and marginal zone lymphoma.

Advances in Later-Lines of Therapy for GIST

April 23rd 2021

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

Targeting PSMA in Advanced Prostate Cancer

March 30th 2021

Experts in genitourinary oncology discuss emerging research surrounding the clinical utility of phenotypic biomarkers, such as prostate-specific membrane antigen (PSMA), for use in the treatment of metastatic castration-resistant prostate cancer.

Examining TKI Combinations in Advanced RCC

March 30th 2021

A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.

HER2+ BC: A Year in Review and Updates from SABCS

January 19th 2021

A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.